Article
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines.
International journal of molecular sciences - 14 Jul 2022
da Silva-Oliveira Renato José, Gomes Izabela Natalia Faria, da Silva Luciane Sussuchi, Lengert André van Helvoort, Laus Ana Carolina, Melendez Matias Eliseo, Munari Carla Carolina, Cury Fernanda de Paula, Longato Giovanna Barbarini, Reis Rui Manuel
Abstract excerpt
Background: EGFR mutations are present in approximately 15−50% of non-small cell lung cancer (NSCLC), which are predictive of anti-EGFR therapies. At variance, NSCLC patients harboring KRAS mutations are resistant to those anti-EGFR approaches. Afatinib and allitinib are second-generation pan-EGFR drugs, yet no predictive biomarkers are known in the NSCLC context. In the present study, we evaluated the efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.